NGM · Biotechnology

Liminatus Pharma, Inc. (LIMN) Stock

$3.70 +0.31% NGM: LIMN Healthcare

Valuation

MetricValue
Price$3.70
Market Cap$4.97M
P/E Ratio-0.14
P/B Ratio5.40
P/S Ratio0.00
EPS (TTM)$-0.43
52-Week High$141.50
52-Week Low$3.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE443.60%
ROA-367.93%
ROCE33.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity4.80
Current Ratio0.10

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-3.0M$-3.0M$-3.0M$-3.0M
Net Profit$4.0M$-3.0M$-1.0M$-3.0M$-10.0M
EPS$6.50$-4.11$-7.50$-20.00$-21.50
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$276.0M$15.0M$5.0M$3.0M$1.0M
Total Liabilities$22.0M$14.0M$15.0M$19.0M$10.0M
Cash$0$5.0M$0$1.0M$0
Borrowings$0$17.0M$16.0M$5.0M$1.0M

Latest News

BC-Most Active Stocks Associated Press · Jul 16, 2026 Top Premarket Gainers MT Newswires · Jul 2, 2026 Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday MT Newswires · Jul 1, 2026 Liminatus Pharma Amends Merger Deal With InnocsAI MT Newswires · Jul 1, 2026 Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-3.0M$-3.0M$-10.0M
Investing Cash Flow$-276.0M$0$-1.0M$2.0M$-1.0M
Financing Cash Flow$-6.0M$-1.0M$0$-2.0M$-3.0M
Net Cash Flow$0$5.0M$-5.0M$1.0M$0
Free Cash Flow$-1.0M$-1.0M$-3.0M$-3.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.24
FCF Yield-86.77%
Quick Ratio1.12
Interest Coverage-53.78
Return 1Y-97.95%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATHEAlterity Therapeutics Limited $4.70 -5.62% -6.89 $42.60M 0.00%
BTAI $0.07 +0.00% -0.02 $2.28M 0.00%
DYAIDyadic International, Inc. $0.44 -0.07% -2.14 $16.18M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is led by CEO Chris Kim, employs 3 people, headquartered in US, publicly traded since 2025.

Liminatus Pharma, Inc. (LIMN) stock trades at $3.70 with a market capitalization of $4.97M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of 5.40, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.29 and $141.50, and currently trades 97.4% below its 52-week high.

On profitability, Liminatus Pharma, Inc. generates a return on equity (ROE) of 443.60% — well above the market average, a sign of a high-quality business, return on capital employed of 33.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides